ABBV 141
Alternative Names: ABBV-141Latest Information Update: 16 Jan 2024
At a glance
- Originator AbbVie
- Class Antifibrotics; Monoclonal antibodies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Fibrosis
Most Recent Events
- 04 Dec 2023 Preclinical trials in Fibrosis in USA (IV)
- 04 Dec 2023 Preclinical trials in Fibrosis in USA (SC)
- 28 Nov 2023 AbbVie plans a phase I trial in Fibrosis (In Volunteers) (SC, IV) in January 2024 (NCT06148181)